ArticleOncotarget2016
NOTUM is a potential pharmacodynamic biomarker of Wnt pathway inhibition.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Discovery of anthraquinones as potent Notum inhibitors for treating osteoporosis by integrating biochemical, phytochemical, computational, and experimental assays.Journal of pharmaceutical analysis · 2026Article
- Comprehensive investigation of multiple targets in the development of newer drugs for the Alzheimer's disease.Acta pharmaceutica Sinica. B · 2025Review
- Wnt5a and Notum influence the temporal dynamics of cartilaginous mesenchymal condensations in developing trachea.Frontiers in cell and developmental biology · 2025Article
- A p300/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models.The Journal of clinical investigation · 2022Article
- Notum palmitoleoyl-protein carboxylesterase regulates Fas cell surface death receptor-mediated apoptosis via the Wnt signaling pathway in colon adenocarcinoma.Bioengineered · 2021Article
- WNT Signaling as a Therapeutic Target for Glioblastoma.International journal of molecular sciences · 2021Review
- Small-molecule inhibitors of carboxylesterase Notum.Future medicinal chemistry · 2021Review
- Carboxylesterase Notum Is a Druggable Target to Modulate Wnt Signaling.Journal of medicinal chemistry · 2021Article
- Article
- Osteoblast-derived NOTUM reduces cortical bone mass in mice and theFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Notum attenuates HBV-related liver fibrosis through inhibiting Wnt 5a mediated non-canonical pathways.Biological research · 2019Article
- Selective Irreversible Inhibitors of the Wnt-Deacylating Enzyme NOTUM Developed by Activity-Based Protein Profiling.ACS medicinal chemistry letters · 2018Article
- From top to bottom: Cell polarity in Hedgehog and Wnt trafficking.BMC biology · 2018Review
- Notum attenuates Wnt/β-catenin signaling to promote tracheal cartilage patterning.Developmental biology · 2018Article
- WNT signalling events near the cell membrane and their pharmacological targeting for the treatment of cancer.British journal of pharmacology · 2017Review
- Molecular genetics and targeted therapy of WNT-related human diseases (Review).International journal of molecular medicine · 2017Article
- Dickkopf-1 Is a Biomarker for Systemic Lupus Erythematosus and Active Lupus Nephritis.Journal of immunology research · 2017Article
- NOTUM Is Involved in the Progression of Colorectal Cancer.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activation of Wnt signaling due to Wnt overexpression or mutations of Wnt pathway components is associated with various cancers. Blocking Wnt secretion by inhibiting PORCN enzymatic activity has shown efficacy in a subset of cancers with elevated Wnt signaling. Predicting response to upstream Wnt inhibitors and monitoring response to therapeutics is challenging due to the paucity of well-defined biomarkers. In this study we identify Notum as a potential biomarker for Wnt driven cancers and show that coordinate regulation of NOTUM and AXIN2 expression may be a useful predictor of response to PORCN inhibitors. Most importantly, as NOTUM is a secreted protein and its levels in blood correlate with tumor growth, it has potential as a pharmacodynamic biomarker for PORCN and other Wnt pathway inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.